GSK/Vertex Lexiva Clears FDA With Food-Free Dosing, Broad Indication
GlaxoSmithKline will likely focus on the dosing flexibility of Lexiva (fosamprenavir), including the option to take with or without food, in its marketing of the protease inhibitor
You may also be interested in...
HHS' revised guidelines for HIV treatment give Abbott's Kaletra a timely endorsement as Bristol-Myers Squibb is launching its competing protease inhibitor Reyataz
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials